AITRICS (CEO Kwang joon Kim), a company specializing in artificial intelligence (AI) technology announced on the 11th that it has signed a Memorandum of Understanding (MOU) with digital healthcare company Mezoo, led by CEO Park Jeong-hwan, for joint product research and development utilizing both companies' products and technologies.

Through this agreement, both parties have committed to: ▲ Conducting research and developing new products using AITRICS’s AI technology and Mezoo’s wearable technology ▲ Exchanging technologies, data, and information, and jointly utilizing facilities and equipment when necessary ▲ Collaborating on joint promotions for major domestic and international clients.

There has been a significant unmet medical need for both hospitalized patients and ambulatory patients, and efforts to address this issue have been ongoing. The goal of both companies is to leverage their unique technologies to develop academic research projects and joint products.

AITRICS-VC (Vital Care) is an AI software that predicts the deterioration of hospitalized patients in terms of sepsis, CPR, and mortality. It is currently implemented in over 40 hospitals in South Korea, including Gangnam Severance Hospital and Korea University Anam and Guro Hospitals, benefiting both healthcare professionals and patients.

Mezoo's HiCardi is a remote electrocardiogram platform that allows real-time monitoring of electrocardiograms, heart rates, body surface temperature, respiration, and sleep anytime and anywhere. It has received recognition not only in the domestic market but also globally.

Both companies expect to enhance the quality of domestic healthcare services through an organic collaboration framework based on their innovative technologies.

Kwang-jun Kim, CEO of AITRICS, stated, “For the development of AI models that analyze biosignals and predict patient deterioration, the accuracy and reliability of sensors are crucial. I expect that this partnership will combine Mezoo’s sensor technology with our AI capabilities to create medical devices that both patients and healthcare professionals can trust. We plan to continue research and development in the field of biosignal-based medical AI and expand our business in close collaboration with Mezoo.”

Park Jeong-hwan, CEO of Mezoo, remarked, “This collaboration with AITRICS, which has outstanding biosignal AI technology, is expected to create synergy for efficient and safe patient management in the future. I anticipate that this agreement will provide a foundation for both companies to enhance monitoring platforms for not only hospitalized patients but also patients outside the hospital.”